ProQR is developing a novel drug, Sepofarsen (QR-110), for patients with Leber’s congenital amaurosis 10. The goal of Sepofarsen is to repair the underlying defect in the RNA and potentially stop the progression of the disease or reverse some effects of LCA10 caused by the p.Cys998X mutation.
